Search company, investor...

BioAssets Development

Founded Year



Unattributed VC | Alive

Total Raised


Last Raised

$3.76M | 14 yrs ago

About BioAssets Development

BioAssets Development Corporation (BDC) is working on indications for marketed and emerging biologic drugs. The company's lead initiative focuses on the development of cytokine inhibitors to treat the underlying causes of pain in spinal disorders.

Headquarters Location

59 Everett Street

Natick, Massachusetts, 01760,

United States

Missing: BioAssets Development's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: BioAssets Development's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing BioAssets Development

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioAssets Development is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

BioAssets Development Frequently Asked Questions (FAQ)

  • When was BioAssets Development founded?

    BioAssets Development was founded in 2005.

  • Where is BioAssets Development's headquarters?

    BioAssets Development's headquarters is located at 59 Everett Street, Natick.

  • What is BioAssets Development's latest funding round?

    BioAssets Development's latest funding round is Unattributed VC.

  • How much did BioAssets Development raise?

    BioAssets Development raised a total of $3.76M.

  • Who are BioAssets Development's competitors?

    Competitors of BioAssets Development include CoMentis, Novira Therapeutics, Santarus, Somaxon Pharmaceuticals, CNSBio and 11 more.

Compare BioAssets Development to Competitors

Ciblex Corporation

Ciblex Corporation is engaged in the development of drugs that impact protein trafficking for use in proliferative disorders.

Jenrin Discovery

Jenrin Discovery, Inc. is developing drugs for the treatment of diabetes and related disorders, by modifying known drugs with CNS side effects to keep them out of the brain. Jenrin has completed initial proof of concept work in animals in their CB1 antagonist program. Additionally, the company is working on peripherally restricted MAO inhibitors, and several other programs.

Richwood Pharmaceutical

Richwood develops drugs for disorders of the central nervous system, particularly hyperactivity in children.


The company is engaged in developing and commercializing drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.

Neurelis Logo

Neurelis is a specialty pharmaceutical company that devleops and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market.

Ikano Therapeutics

Ikano Therapeutics is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products with a particular focus on drugs treating pain and disorders related to the central nervous system.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.